Sierra-Madero Juan, Di Perri Giovanni, Wood Robin, Saag Michael, Frank Ian, Craig Charles, Burnside Robert, McCracken Jennifer, Pontani Dennis, Goodrich James, Heera Jayvant, Mayer Howard
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CIFBIOTEC Medica Sur, Tlalpan, Mexico.
HIV Clin Trials. 2010 May-Jun;11(3):125-32. doi: 10.1310/hct1103-125.
The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay.
Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed.
Proportions of subjects <50 copies/mL (58.8% maraviroc, 62.7% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5% vs 60.7%) were similar. Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm(3)) and fewer adverse event discontinuations (6.1% vs 15.5%), malignancies, and category C events.
Week 96 data confirm week 48 observations in MERIT.
MERIT研究评估了马拉维罗与依非韦伦（两者均联合齐多夫定/拉米夫定）在初治的CCR5嗜性（R5）HIV-1患者中的疗效。事后分析先前评估了通过更敏感的嗜性检测重新筛查出R5病毒的患者在第48周时的结局。
评估了第96周的疗效（事后分析，n = 614）和安全性（n = 721）。
病毒载量<50拷贝/毫升的受试者比例（马拉维罗为58.8%，依非韦伦为62.7%）以及病毒学应答丧失时间（TLOVR）的应答者比例（<50拷贝/毫升：60.5%对60.7%）相似。接受马拉维罗治疗的患者CD4增加更多（+212对+171个细胞/立方毫米），因不良事件停药的情况更少（6.1%对15.5%），恶性肿瘤和C类事件也更少。
第96周的数据证实了MERIT研究中第48周的观察结果。
